Autoimmune Diseases Working Party (ADWP)
Type of Stem Cell Treatment:
CMV EBV reactivation
To identify the cumulative incidence, risk factors and outcome of CMV/EBV viraemia (ie, virus detection without clinical symptoms), CMV/EBV disease (ie, detection of viraemia and clinically relevant end organ disease) and CMV/EBV clinically significant infection (CMV/EBV viraemia leading to pre-emptive treatment) in patients who received autologous HSCT for an autoimmune disease (AD) at 100 days and 1 year following auto-HSCT. To assess centre practice in screening and treatment of CMV and EBV in the context of auto-HSCT for AD.
Key inclusion criteria:
All patients registered in the EBMT database receiving a first autologous HSCT for AD between 2009 and 2019
EBMT Study coordinator:
Study coordinator email: